Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026
Trevi Therapeutics announced that senior management will host a conference call and live audio webcast on May 5, 2026, to report Q1 2026 financial results and provide a corporate update. The company is a clinical-stage biopharmaceutical firm developing Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with IPF, non-IPF ILD, and RCC.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.